Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACTS Dr Marcel Tigges Chief Scientific Officer Dr Marc Gitzinger Chief Executive Officer Patrick Burgermeister Advisor ADDRESS BioVersys AG c/o Technologiepark Basel Hochbergerstrasse 60c CH-4057 Basel Switzerland TELEPHONE +41 61 633 22 50 +41 61 633 22 51 FAX +41 61 633 22 59 EMAIL info@bioversys.com marcel.tigges@bioversys.com Marc.gitzinger@bioversys.com Patrick.burgermeister@eisei.ch YEAR FOUNDED 2010 BioVersys AG www.bioversys.com FINANCIAL SUMMARY Seed Round: CHF 2.5 million (2011) Series A: CHF 12 million expected for end 2012 COMPANY PROFILE BioVersys is a privately held Swiss bio-pharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. BioVersys has developed a proprietary multi-level screening technology to identify small chemical molecules that interfere with bacterial transcriptional regulators. These Transcription Regulator Inhibitory Compounds (TRICs) are able to switch off bacterial resistance at a genetic level and thus reactivate ineffective antibiotics. Currently, the company has identified active TRIC molecules acting against gram negative and gram positive pathogens. In collaboration with the INSERM Lille the company also follows a program directed against multi drug resistant Tuberculosis MANAGEMENT Dr Marc Gitzinger, co-founder and CEO Dr Marcel Tigges, co-founder and CSO t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACTS Andreas Caduff, PhD Chief Executive Officer Mark Talary, PhD Chief Technical Officer ADDRESS Technoparkstr. 1 8005 Zurich Switzerland TELEPHONE +41 44 515 61 71 +41 79 677 41 79 FAX +41 44 515 61 71 EMAIL andreas.caduff@biovotion.com YEAR FOUNDED 2011 (taken over IP and technology from former Solianis) BioVotion AG www.biovotion.com FINANCIAL SUMMARY BioVotion is currently raising a CHF5.5M Series B round for product finalization, further clinical testing, regulatory approval, production ramp-up and initial market launch. Revenue generation is expected within 12 to 18 months. Revenues in the European COPD market, the first of several addressable markets, should reach around CHF30M by 2016. Cash break-even is envisaged for late 2015. COMPANY PROFILE BioVotion AG is a Swiss based medical device company, providing solutions for continuous, non-invasive physiological monitoring. The BioVotion Vital Sign Monitoring (VSM) platform is a mobile, standalone wearable monitor of vital sign parameters supported by integrated cloud services for data exchange and analysis. It is directed towards patients with chronic conditions featuring BioVotion’s patient-friendly, wearable monitoring concept. The company holds internationally recognised know how in a number of fields, relevant to provide sensor technology and device development for continuous and non-invasive physiological monitoring, embedded into mHealth environments. MANAGEMENT BioVotion AG is a Swiss medical device company established by leading and experienced experts in the field of sophisticated, wearable monitoring. Andreas Caduff, PhD, Chief Executive Officer Mark Talary, PhD, Chief Technical Officer t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37: CONTACTS Tom Kronbach, PhD Chief Ex
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90:
CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92:
CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94:
CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96:
CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?